Cargando…

Is there a rationale for heparin use among severe COVID-19 patients?

Detalles Bibliográficos
Autor principal:	Savioli, Felicio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto Israelita de Ensino e Pesquisa Albert Einstein 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239568/ https://www.ncbi.nlm.nih.gov/pubmed/32490886 http://dx.doi.org/10.31744/einstein_journal/2020ED5758

Ejemplares similares

Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?
por: Savioli, Felicio, et al.
Publicado: (2022)

Serotonin reuptake inhibitors and bleeding risks related to elderly submitted to major orthopedic surgery
por: Savioli, Felicio
Publicado: (2019)

Coagulation profile in severe COVID-19 patients: what do we know so far?
por: Savioli, Felicio, et al.
Publicado: (2020)

The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
por: Reichman-Warmusz, Edyta, et al.
Publicado: (2022)

Surviving Covid-19 with Heparin?
por: ten Cate, Hugo
Publicado: (2021)

Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
por: Magnani, Harry N.
Publicado: (2021)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Chloroquine for COVID-19: rationale, facts, hopes
por: Cortegiani, Andrea, et al.
Publicado: (2020)

Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
por: van Haren, Frank M. P., et al.
Publicado: (2020)

Heparin-Induced Thrombocytopenia in Severe COVID-19
por: Daviet, Florence, et al.
Publicado: (2020)

To heparinize or not to heparinize: Effect on arterial blood gas measurements
por: Lobo, Valentine
Publicado: (2014)

Thromboelastometry Identified Alteration of Clot Stabilization and Factor XIII Supplementation Need in a Patient with Decompensated Liver Disease Undergoing Liver Biopsy
por: Crochemore, Tomaz, et al.
Publicado: (2018)

Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines
por: Porfidia, Angelo, et al.
Publicado: (2020)

Copper-Heparin Inhalation Therapy To Repair Emphysema: A Scientific Rationale
por: Janssen, Rob, et al.
Publicado: (2019)

Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report
por: Crochemore, Tomaz, et al.
Publicado: (2018)

Rationale for combined therapies in severe-to-critical COVID-19 patients
por: Gonzaga, Aitor, et al.
Publicado: (2023)

Compensatory effect of fibrinogen in a patient with bone marrow aplasia, septic shock, and severe thrombocytopenia guided by thromboelastometry: a case report
por: Crochemore, Tomaz, et al.
Publicado: (2018)

The Rationale of Influenza
Publicado: (1891)

Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders
por: Villoutreix, Bruno O., et al.
Publicado: (2020)

COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No
por: Jimenez, David, et al.
Publicado: (2022)

Timing of Endotracheal Intubation and Mortality among Patients with Severe COVID-19
por: Ray, Banambar, et al.
Publicado: (2021)

Advances in Heparins and Related Research. An Epilogue
por: Fareed, Jawed, et al.
Publicado: (2018)

Rationale of the Action of Cocaine
Publicado: (1885)

POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes
por: Tritschler, Tobias, et al.
Publicado: (2022)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
por: Streng, Alexander S., et al.
Publicado: (2020)

Thromboelastometry early identifies thrombotic complications related to COVID-19: A case report
por: Araújo San Martin, Raíssa Lanna, et al.
Publicado: (2021)

What's new in emergencies, trauma, and shock? Heparin in severe traumatic brain injury: Beyond venous thromboembolism prevention?
por: Masotti, Luca, et al.
Publicado: (2014)

The scientific rationale for the use of simple masks or improvised facial coverings to trap exhaled aerosols and possibly reduce the breathborne spread of COVID-19
por: Pleil, Joachim D, et al.
Publicado: (2020)

The versatile heparin in COVID‐19
por: Thachil, Jecko
Publicado: (2020)

Heparin Induced Thrombocytopenia in Patients with COVID-19
por: Warrior, Surbhi, et al.
Publicado: (2020)

New developments in the characterization of heparin and its impurities
por: Larive, Cynthia K.
Publicado: (2010)

Novel Antagonists of Heparin Binding Growth Factors
por: Cecchi, Fabiola, et al.
Publicado: (2012)

Rationale for launching a new journa
por: Nitrini, Ricardo
Publicado: (2007)

A Rationale for the Use of Norepinephrine after the Control of Bleeding in Hemorrhagic Shock?
por: Asfar, Pierre, et al.
Publicado: (2022)

Introduction to the Molecules Special Edition Entitled ‘Heparan Sulfate and Heparin: Challenges and Controversies’: Some Outstanding Questions in Heparan Sulfate and Heparin Research
por: Yates, Edwin A, et al.
Publicado: (2019)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Prognostic value of heparin-binding protein for mortality in severe COVID-19 pneumonia
por: Acar, Tarık, et al.
Publicado: (2022)

Rationale of anticoagulation among patients of COVID-19 undergoing cardiac surgery
por: Sharma, Dhruva
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3h53043skmhc7mc5jlregq9eci